AVEO Oncology (AVEO) – Company Press Releases
-
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
-
2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers
-
LG Chem Completes Acquisition of AVEO Oncology
-
AVEO Oncology Stockholders Approve Acquisition by LG Chem
-
AVEO Oncology Stockholders Approve Acquisition by LG Chem
-
AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders
-
AVEO Oncology Reports Third Quarter 2022 Financial Results
-
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
-
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
-
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma
-
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
-
AVEO Oncology Announces Participation at Investor Conferences in September
-
AVEO Oncology Reports Second Quarter 2022 Financial Results
-
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with
-
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
-
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
-
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
-
AVEO Oncology Reports First Quarter 2022 Financial Results
-
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
-
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
-
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
-
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
-
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
-
AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference
-
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatme
-
AVEO Oncology Highlights Recent Progress and 2022 Outlook
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastati
-
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
-
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
-
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
-
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
-
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
-
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
-
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
-
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
-
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
-
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
-
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
-
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
-
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
-
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
-
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
-
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
-
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
-
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines
-
AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
-
AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock
-
AVEO Announces Proposed Public Offering of Common Stock
-
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
Back to AVEO Stock Lookup
